| Patient |
Disease stage |
Se× and age at 131I-mIBG treatment [years] |
Weight at 131I-mIBG treatment [kg] |
Biology of NB |
Distribution of 123I-mIBG positive lesions pre-treatment |
Outcome status at time of consent for publication [months after 131I-mIBG treatment] |
| 1 |
Refractory |
Boy, 2 |
17 |
MYCN-not amplified, no chromosomal segmental aberrations |
Diffuse skull uptake |
Alive with positive mIBG uptake, off treatment, well [36 months] |
| 2 |
Refractory |
Girl, 2 |
13 |
MYCN-not amplified, no chromosomal segmental aberrations |
Diffuse widespread skeletal uptake |
Alive with positive mIBG uptake, off treatment, well [25 months] |
| 3 |
Relapse × 1 |
Boy, 11 |
29 |
MYCN-not amplified, 11q23 deletion |
Localized lesion left tibia |
New localized relapse at another skeletal location 16 months later, under treatment [24 months] |
| 4 |
Relapse × 3 |
Girl, 7 |
33 |
MYCN-gain, no other chromosomal segmental aberrations |
Localized lesion L1 |
Alive with positive mIBG uptake, off treatment, well [22 months] |
| 5 |
Relapse × 1 |
Boy, 8 |
35 |
MYCN-not amplified, 11q23 deletion, 17q gain |
Minimal retro-peritoneal uptake and sparse uptake localized right tibia |
Alive without signs of disease, still on treatment [5 months] |
